Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Inhaled RCVi COVID-19 Vaccine in Healthy Adults
NCT05706324Phase 1Unknown
- Sponsor
- Wuhan BravoVax Co., Ltd
- Start
- Jun 2023
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of recombinant COVID-19 vaccine (chimpanzee adenovirus vector) for inhalation in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Wuhan BravoVax Co., Ltd. Primary endpoints: Safety in terms of adverse events, Safety in terms of solicited AEs at 7 days and 4 more. Status: unknown.
02
Drugs
recombinant COVID-19 vaccine (chimpanzee adenovirus vector) for inhalation
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05706324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05706324.